Prinova introduces nanoparticle-free vitamin D powders

In addition to immune health, vitamin D is associated with a wide range of other benefits including promoting cardiovascular health, boosting mood and providing weight loss support

Prinova has developed a line of nanoparticle-free vitamin D powders for food, beverage and nutrition businesses. Oil-based formats are also available.

Prinova’s vitamin D portfolio comprises vitamin D3 from cholecalciferol, which is manufactured in Europe, and vitamin D2 from ergocalciferol, which is made in the USA and is suitable for vegans.

In powder form, both are free-flowing and offer dispersibility despite not containing any anti-caking agents. This is increasingly a key selling point, Prinova says, with consumer concern mounting in relation to the safety of nanoparticles, especially in infant nutrition products.

Vitamins D3 and D2 from Prinova are suitable for a wide range of applications, including infant nutrition, supplements, dairy, beverages, cereals, bars, and sports nutrition. They are non-GMO and Halal certified and offer stability even at higher temperatures, the company says.

Tony Gay, Head of Technical Sales & NPD for Nutrition Division at Prinova Europe, said: “Products containing Vitamin D are enjoying a wave of popularity and while this is a great opportunity it also makes the category fiercely competitive. Prinova’s vitamins D3 and D2 provide an edge so that manufacturers can create products that address consumers’ concerns and align with their preferences.”

For children and teenagers, D vitamins are essential for the development of healthy bones and teeth, for muscle function, normal neurotransmission, blood clotting, and digestive enzymes. Women who are pregnant or lactating, or experiencing menopause, need vitamin D for its ability to promote better calcium absorption.

This benefit is also important for post-menopausal women, who are at a high risk of osteoporosis, with 70% suffering from the condition. It is forecast that there will be a 26.2% increase in osteoporosis-related fractures from 2017 to 2030, highlighting the scale of this issue.

Companies